topic

Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients
Georg Alexander Rockinger, Philippe Guillaume, Amélie Cachot, Margaux Saillard, Daniel E Speiser, Georges Coukos, Alexandre Harari, Pedro J Romero, Julien Schmidt, Camilla Jandus

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000435; DOI: 10.1136/jitc-2019-000435
EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
Dong Jun Park, Pil Soo Sung, Jung-Hee Kim, Gil Won Lee, Jeong Won Jang, Eun Sun Jung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000301; DOI: 10.1136/jitc-2019-000301
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
Daan P. Hurkmans, Edwin A. Basak, Nina Schepers, Esther Oomen-De Hoop, Cor H. Van der Leest, Samira El Bouazzaoui, Sander Bins, Stijn L. W. Koolen, Stefan Sleijfer, Astrid A. M. Van der Veldt, Reno Debets, Ron H. N. Van Schaik, Joachim G. J. V. Aerts, Ron H. J. Mathijssen

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000586; DOI: 10.1136/jitc-2020-000586
Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy
Brett A Schroeder, Ralph Graeme Black, Sydney Spadinger, Shihong Zhang, Karan Kohli, Jianhong Cao, Jose G Mantilla, Ernest U Conrad, Stanley R Riddell, Robin L Jones, Cassian Yee, Seth M Pollack

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000247; DOI: 10.1136/jitc-2019-000247
Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
Dawei Chen, Hari Menon, Vivek Verma, Chunxiao Guo, Rishab Ramapriyan, Hampartsoum Barsoumian, Ahmed Younes, Yun Hu, Mark Wasley, Maria Angelica Cortez, James Welsh

Journal for ImmunoTherapy of Cancer Jan 2020, 8 (1) e000492; DOI: 10.1136/jitc-2019-000492
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
Ashley M Hopkins, Ganessan Kichenadasse, Chris S Karapetis, Andrew Rowland, Michael J Sorich

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000500; DOI: 10.1136/jitc-2019-000500
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
Coya Tapia, Phyu P. Aung, Sinchita Roy-Chowdhuri, Mingxuan Xu, Fengying Ouyang, Anas Alshawa, Joud Hajjar, Gopal Singh, Vincent Yang, Lilibeth Castillo, Hung Le, Ravi Murthy, Bettzy Stephen, Kenneth R Hess, Ignacio Wistuba, Aung Naing

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000665; DOI: 10.1136/jitc-2020-000665
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
Katsuyuki Hotta, Nobukazu Fujimoto

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000461; DOI: 10.1136/jitc-2019-000461
Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000798corr1; DOI: 10.1136/jitc-2020-000798corr1
FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion
Robert J Oldham, C Ian Mockridge, Sonya James, Patrick J Duriez, H T Claude Chan, Kerry L Cox, Vicentiu A Pitic, Martin J Glennie, Mark S Cragg

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000619; DOI: 10.1136/jitc-2020-000619

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages